Clinical trial
A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD
NCT00601367 is registered in ClinicalTrials.gov with Sprout Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD
- Lead sponsor
- Sprout Pharmaceuticals, Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- October 31, 2009
- Enrollment
- 480 (actual)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.